lamivudine has been researched along with Neoplasms in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Razlansari, M; Shahabadi, N; Zhaleh, H | 1 |
| Baldin, G; Bellino, S; Belmonti, S; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Dusina, A; Emiliozzi, A; Lamonica, S; Lombardi, F; Moschese, D; Pezzotti, P; Tamburrini, E; Visconti, E; Whalen, M | 1 |
| Arshad, B; Chen, HR; Dai, W; Kong, LQ; Li, X; Wu, H; Wu, KN; Wu, YT; Xu, Z | 1 |
| Balci, E; Hascuhadar, M; Oksuzoglu, B; Turker, K; Uyeturk, U | 1 |
| Aykas, F; Basak, M; Karahan, S; Karaman, A; Oguz, A; Unal, D; Uslu, E | 1 |
| Bagal, B; Bhat, V; Gawande, J; Gupta, A; Kannan, S; Khattry, N; Mathew, L; Punatar, S | 1 |
| Heathcote, EJ; Ho, EY; Lau, GK; Rousseau, F; Yau, T | 1 |
| Chan, HH; Chang, HW; Chen, WC; Cheng, JS; Chiang, PH; Hsu, PI; Lai, KH; Tsai, WL; Tsay, FW; Yu, HC | 1 |
| An, J; Choi, J; Chung, YH; Kim, KM; Kim, SO; Kim, SW; Lee, D; Lee, HC; Lee, YS; Lim, YS; Shim, JH; Suh, DJ | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Brancaccio, G; Ciardiello, F; Dallio, M; Del Prete, S; Fabozzi, A; Federico, A; Gaeta, GB; Iodice, P; Loguercio, C | 1 |
| Arslan, U; Artac, M; Basaranoglu, M; Boruban, MC; Eren, OO; Yavas, O | 1 |
| Li, DJ; Liu, C; Liu, L; Lu, LX; Lu, XJ; Tang, H; Wang, LC; Wang, Y; Xu, KW | 1 |
| Kim, BG; Kim, D; Kim, IK; Kim, W; Kim, YJ; Lee, HS; Yoon, JH | 1 |
| Chen, J; Chen, ZH; Dong, M; Li, X; Lin, Q; Lin, ZX; Ma, XK; Ruan, DY; Wan, XB; Wang, TT; Wei, L; Wen, JY; Wu, XY; Xing, YF | 1 |
| Maeda, Y; Okamoto, R; Sasaki, T | 1 |
| Chan, AT; Chan, PK; Ho, WM; Johnson, PJ; Lam, KC; Lee, JJ; Lei, KI; Leung, TW; Mok, TS; Yeo, W; Zee, B; Zhong, S | 1 |
| Jia, J; Lin, F | 1 |
| Demir, H; Gürakan, F; Ozen, H; Saltik-Temizel, IN; Usta, Y; Yüce, A | 1 |
| Choi, KH; Hong, SP; Hwang, SG; Kim, S; Ko, KH; Kwon, CI; Lee, JH; Oh, D; Park, PW; Rim, KS | 1 |
| Chen, XY; Dong, JL; Huang, CY; Ma, LN; Sun, GZ | 1 |
| Csako, G; Hoofnagle, JH; Liang, TJ; Loomba, R; Pucino, F; Rowley, A; Wesley, R | 1 |
| Altintas, A; Bayan, K; Cil, T; Isikdogan, A; Ozekinci, T; Pasa, S | 1 |
| Chan, PK; Johnson, PJ; Lam, KC; Leung, NW; Mok, TS; Steinberg, JL; Tam, JS; Yeo, W | 1 |
| Chan, PK; Ho, WM; Hui, P; Johnson, PJ; Leung, NW; Steinberg, JL; Tam, JS; Yeo, W; Zee, B; Zhong, S | 1 |
3 review(s) available for lamivudine and Neoplasms
| Article | Year |
|---|---|
Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B; Humans; Lamivudine; Neoplasms; Retrospective Studies; Virus Activation | 2018 |
[Hepatotoxicity of chemotherapy].
Topics: Antineoplastic Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Hematologic Neoplasms; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Liver Diseases; Neoplasms; Reverse Transcriptase Inhibitors | 2003 |
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Liver Failure, Acute; Neoplasms; Virus Activation | 2008 |
6 trial(s) available for lamivudine and Neoplasms
| Article | Year |
|---|---|
Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Neoplasms; Organophosphonates; Virus Activation; Young Adult | 2015 |
Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience.
Topics: Anti-HIV Agents; Antineoplastic Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Neoplasms; Retrospective Studies; Treatment Outcome; Virus Activation | 2009 |
[Effect of Lamivudine on chronic hepatitis B patients with chemotherapy or immunosuppressive agents therapy and research the drug resistance].
Topics: Adult; Antineoplastic Agents; Drug Resistance; Female; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Neoplasms; Reverse Transcriptase Inhibitors; Rheumatic Diseases; Young Adult | 2011 |
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Topics: Adult; Age Distribution; Aged; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Incidence; Lamivudine; Male; Middle Aged; Neoplasm Staging; Neoplasms; Primary Prevention; Probability; Prognosis; Reference Values; Risk Assessment; Secondary Prevention; Serologic Tests; Sex Distribution; Survival Analysis; Treatment Outcome | 2004 |
[A clinical analysis of HBV reactivation in patients with malignant tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Neoplasms; Virus Activation | 2007 |
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Agents; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Prevalence; Treatment Outcome; Virus Activation | 2008 |
16 other study(ies) available for lamivudine and Neoplasms
| Article | Year |
|---|---|
Topics: Hydrogen-Ion Concentration; Hydroxides; Lamivudine; Magnetics; Magnetite Nanoparticles; Nanoparticles; Neoplasms | 2022 |
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital.
Topics: Adult; Anti-HIV Agents; Cohort Studies; HIV Infections; Hospitals; Humans; Italy; Lamivudine; Longitudinal Studies; Male; Neoplasms; Pharmaceutical Preparations | 2021 |
Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Clinical Competence; Female; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Practice Patterns, Physicians' | 2013 |
Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy.
Topics: DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Lamivudine; Liver Function Tests; Male; Middle Aged; Neoplasms; Retrospective Studies; RNA, Viral; Seroepidemiologic Studies | 2014 |
Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.
Topics: Adolescent; Adult; Allografts; Autografts; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B virus; Humans; Infant; Lamivudine; Male; Middle Aged; Neoplasms; Virus Activation | 2016 |
A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Topics: Antiviral Agents; Demography; DNA, Viral; Female; Guanine; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Treatment Outcome; Virus Activation; Withholding Treatment | 2015 |
Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
Topics: Adult; Alanine Transaminase; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Guanine; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Assessment; Viral Load; Virus Activation | 2016 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Italy; Lamivudine; Male; Middle Aged; Neoplasms; Virus Activation | 2017 |
Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Rituximab; Survival Rate; Treatment Failure; Viral Load | 2012 |
An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antiviral Agents; Female; Hepatitis Antigens; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Pilot Projects; Reverse Transcriptase Inhibitors; Secondary Prevention; Survival Rate; Treatment Outcome; Virus Activation; Young Adult | 2013 |
[Lamivudine therapy for prevention of chemotherapy-induced reactivation of hepatitis B virus].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Female; Hepatitis B, Chronic; Humans; Lamivudine; Lymphoma; Male; Middle Aged; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Secondary Prevention; Stomach Neoplasms | 2004 |
Five-year results of chronic hepatitis B infection treatment in children with cured cancer.
Topics: Adolescent; Adult; Alanine Transaminase; Child; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Male; Neoplasms | 2006 |
[Hepatitis B and C virus infection and liver dysfunction in patients receiving chemotherapy].
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis B; Hepatitis C; Humans; Lamivudine; Liver Diseases; Male; Middle Aged; Neoplasms; Prevalence | 2006 |
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
Topics: Adult; Antiviral Agents; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Treatment Outcome; Virus Activation | 1999 |
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
Topics: Adult; Age Factors; Alanine Transaminase; Female; Hepatitis Antibodies; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Humans; Immunosuppressive Agents; Incidence; Lamivudine; Liver Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Factors; Sex Factors; Virus Activation | 2000 |